Member Info for inanaco

some seriously intelligent people do not thing so ...

and just looked at your early statement on education

"""" and that's me educated guess."""" ... you posted surprised you did not put "man" after it ...

would sound better ... "and that's me educated guess man" ...

can you please expand on your education, so that we can be more informed ? as clearly you are using it to claim "superiority"

What exactly happened to yours ... ?

why did you go Off the Grid ?

Member Since: Tue, 9th Jul 2013

since you have been back why are all your posts on SCLP ?

what is the fascination ?

i referred to my previous post

Scancell is a science based research company that is NOT intending to take Scancell tech to a Phase 3 ...

as such we await deals based around 3 platforms at phase 2 or in the TCR case advanced preclinical

its a waiting game

If you have not understood what Scancell is about, then that would reflect it your posts which it does

we are "Waiting a Deal" ... so SP not relevant in that respect, but is if we have to fund based around that SP

However as we have seen funding of the IP can appear from sources that we least expected ,, CRUK

so again speculating is pointless ...

""" When we suffer """ ... who suffers ? most of us on here are buyers not sellers .. and are you now claiming to Hold while explaining why we should not ?

Knowlesi ...

BODS interest not aligned with shareholders .....

what does that mean ?

when the major shareholders are putting up the funds and indeed Pi contributed in the last fund raise

------------------------------------------------------------------------------------------------------------------------------------------------------

"the Summer dilutive fund raise likely"

is just purely speculative as scancell has a potential "deal" lined up, and the fact that TCR experts have joined the company together with manufacturing experts, the BOD seems to be doing things that don't actually align with your statement

all you want to do is push a negative perspective that is unproven and speculative at best ... you could not class it as even an alternative view .. because it does not contain any new information

RECs

just because you got 8 VAL shareholders to support you does not mean you have won the lottery ...

we don't ramp ... this is not the VAL bb

Clearly you not transparent ...... so "motive" is an issue

ATB have a good weekend ...

not at all ...... just highlighting that we have been informed already that FDA and Ichor are sorting out issues and Modi1 issues have been sorted ... Nothing's changed

the fact that you are indeed "private" in your transactions on this share suggests you are playing Poker ... a game of Bluff

can you "Sell" sentiment .. to the gullible because that is all you are doing

while the rest of us hold for deals ............ not small SP movements, because we know the size of the deals that Scancells Technology can Generate ..

ATB

so are you looking to buy ??? or are you saying you did not know or understand what you bought into ?

which is it ? Knowlesi ?

Not at all ..

Scancell is a science research based organisation ...

1/ It will eat money
2/ if you cannot value or understand the IP they are developing .. don't invest
3/ value is generated by trials which are on track as per january statements but the cause in the delay is not management its ichor and the technical challenge of a complex conjugate
4/scancell has strengthen TCR and Manufacturing expertise
5/ Scancell management are all from a technical background and can easily present Scancell

fact that you are here ..are you trying to buy ? or are you here trying to sell ?

cant be both unless you are a shareholder .. and they way you post, it does not sound like it ...

if it's that bad why are you here ? again you would have not come back on to post !! unless you wanted to buy ...

or was your absence to rebuild your capital base to try again ?

psychology

reverse phycology if the science was good enough to buy at 7p ... then 6p is a bargain ... after all NOTHING has changed since the January Updates ...

apart From Knowlesi constantly attacking the share while at the same time being positive on the science ..

point being only the science is up for deals ... and buyers actually ignore salesman, if your astute ... so this management "question" is actually hot air

Moditope experts are in the FDA ... for example ?

which is why the go through this exhausting preclinical checklist ...

for instance why do you need such exhaustive Toxicology studies on a peptide (protein ) after all it's just a tiny "steak" LOL

https://www.celerion.com/wp-content/uploads/2017/03/Celerion_Accelerating-Peptides-into-Human-Studies_TIDES_F.pdf

one other point when you take your car for an MOT .. the tester actually knows what he is doing ...

a "new device" does not have an expert examiner by the very nature the examiner did not "invent" the device

the FDA are in a "learning curve" with every application ...

"deadline" is not the best language C7 ....

appreciate that everything Scancell does ... by its very nature is "new" ....

so timelines are approx

https://www.bbc.co.uk/news/science-environment-47469071

hardly .... the "ichor device" on Mars has hit Rocks ... LOL its taking a rest before having another go

it's frustrating as the science behind all this is so exciting ... and to have developed the understanding to appreciate the value ... even more so which the market will come to accept over time

keytruda is nothing to do with Ichor C7 .. as this is a device issue not a "clinical hold" i have asked Scancell this very specific question ...

would not be concerned C7 ... news will arrive soon enough, FDA is slow, what i never understand with bureaucracy because Ichor Trigrid 2 is already in use in patients why can't they deal with whatever issues they have while the trial is running ... after all its a needle and a zap ... hardly life threatening. and at this late stage with the experience ichor have you would have thought the FDA would be more sympathetic indeed with the US Government also involved with its development .. The United States Army Medical Research Institute of Infectious Diseases

Immune suppression development will not stop at PD-1 ...

Stevenage, United Kingdom – September 28th 2018: Tusk Therapeutics Ltd (“Tusk”) was today acquired by Roche. Tusk has developed an antibody with a novel mode of action aimed at depleting regulatory T-cells (Tregs). Tregs suppress immune responses, including those against cancer cells. Preclinical data has shown that depleting Tregs from the tumor microenvironment can enhance and/or restore anti-tumor immunity. Tusk’s antibody has been designed to deplete these harmful Tregs, while not interfering with other immune cells acting against the tumor. Tusk’s program is expected to start clinical trials in cancer patients towards the end of 2019.

Roche will pay up to $759m for its acquisition of Tusk Therapeutics, a UK-based company which develops immuno-oncology treatments. The payments will be made with €70m ($81m) upfront with up to €585m ($678m) being payable in milestones.

so i would not worry about SP growth when it happens

that should enter trial soon ... if it works .. It could work with SCIB1 and keytruda ...

It could also potentially help flip the Immunosuppressive Cd4+cd25 t cell regulatory cells with Moditope .....

is Genentech out of the picture ?

No